Equities

Ind Swift Ltd

INDSWFTLTD:NSI

Ind Swift Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)23.60
  • Today's Change-0.300 / -1.26%
  • Shares traded26.31k
  • 1 Year change+5.59%
  • Beta0.8133
Data delayed at least 15 minutes, as of Sep 20 2024 11:18 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ind Swift Limited is an India-based company, which is engaged in manufacturing and trading of pharmaceutical and healthcare products. The Company's divisions include Nova Division, Ethical Division, Generic Division, and Ayurveda Division. The Nova Division is a multispecialty division. Its portfolio covers all the therapeutic segments which are available in all the other divisions like respiratory inclusive of ENT, dentistry, anti-infective, cardio-diabetic and orthopedic therapies. The Nova Division Products include Aclovin, Aclovin - SR, Adelive oil and Agipod D/S. The Ethical Division is focused on gynecology, pediatrics, dermatology and GP and its ambit extends to a wide range of medicines. The Generic Division is divided into various therapeutic segments, namely antibiotic, anti-cold, nutraceuticals, anti-diarrhoeal, anti-malarial and anti-depressants. The Ayurveda Division's products include Swift Hangover Capsules, Oliade Oil, Swift Tulsi Drops and Majitrich Capsules.

  • Revenue in INR (TTM)4.68bn
  • Net income in INR401.08m
  • Incorporated1986
  • Employees1.67k
  • Location
    Ind Swift Ltd781, Industrial Area,Phase II,CHANDIGARH 160002IndiaIND
  • Phone+91 1 724680800
  • Fax+91 1 722652242
  • Websitehttp://www.indswiftltd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ind Swift Ltd4.68bn401.08m1.28bn1.67k3.18--1.940.27347.427.4286.37-------------0.902----45.6345.728.58-1.44--0.1318----22.2111.68-45.3411.6815.24--
Lasa Supergenerics Ltd1.05bn-195.13m1.31bn77.00------1.25-3.92-3.9220.94--------13,586,300.00---3.86---5.3426.4132.53-18.65-5.30---4.49-----19.47-9.2643.73------
Biofil Chemicals and Pharmaceuticals Ltd460.45m6.34m1.36bn--210.16--132.742.950.39780.397828.96------------2.74--5.364.949.991.382.80--7.63----33.2911.6026.558.02-56.15--
Vaidya Sane Ayurved Laboratories Ltd1.05bn36.30m1.58bn632.0043.362.8723.651.513.463.4699.5552.121.7411.9020.171,654,093.006.04--7.39--71.79--3.47--2.5716.250.0683--32.55--49.62------
Data as of Sep 20 2024. Currency figures normalised to Ind Swift Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.